Equities

Consun Pharmaceutical Group Ltd

Consun Pharmaceutical Group Ltd

Actions
  • Price (HKD)8.60
  • Today's Change0.12 / 1.42%
  • Shares traded1.47m
  • 1 Year change+84.95%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Consun Pharmaceutical Group Ltd grew revenues 10.71% from 2.34bn to 2.59bn while net income improved 14.88% from 682.91m to 784.53m.
Gross margin74.22%
Net profit margin30.66%
Operating margin34.59%
Return on assets15.97%
Return on equity23.91%
Return on investment23.24%
More ▼

Cash flow in CNYView more

In 2023, Consun Pharmaceutical Group Ltd increased its cash reserves by 12.17%, or 298.09m. The company earned 818.97m from its operations for a Cash Flow Margin of 31.62%. In addition the company used 231.77m on investing activities and also paid 280.10m in financing cash flows.
Cash flow per share1.24
Price/Cash flow per share7.29
Book value per share4.77
Tangible book value per share4.42
More ▼

Balance sheet in CNYView more

Consun Pharmaceutical Group Ltd appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 2.75bn. In fact, 0.38% of the value of Consun Pharmaceutical Group Ltd shares can be attributed to this cash.
Current ratio3.06
Quick ratio2.80
Total debt/total equity0.1393
Total debt/total capital0.1144
More ▼

Growth rates in CNY

SmartText is unavailable
Div yield(5 year avg)7.68%
Div growth rate (5 year)18.43%
Payout ratio (TTM)53.59%
EPS growth(5 years)13.12
EPS (TTM) vs
TTM 1 year ago
12.05
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.